New diabetes drug candidate tested in early trial
NCT ID NCT07535307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests how a new medicine, NNC0487-0111, affects insulin sensitivity and pancreas function in adults with type 2 diabetes. About 80 participants will receive either the study drug or a placebo. The goal is to see if the drug can help the body use insulin better and improve how the pancreas works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil Institut für Stoffwechselforschung GmbH
RECRUITINGNeuss, 41460, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personality type may influence diabetic wound healing – a study investigates
- Quitting smoking may also ward off diabetes — a trial puts the dual strategy to the test
- Could a simple clinic Check-In change catch hidden high blood pressure and diabetes?
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- Eye scan may spot hidden blood-flow changes that signal glaucoma risk in diabetes
- Tight glucose control may preserve insulin-making cells in type 2 diabetes